Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henrik Støvring

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Ugeskrift for Laeger|January 14, 2004
[Occurrence of diabetes in Denmark: development of methods for registry-based assessment]Henrik Støvring
Ugeskrift for Laeger|December 10, 2002
[New biostatistical methods in general practice research. A literature review]Henrik Støvring
Pharmacoepidemiology and Drug Safety|April 26, 2007
Selection bias due to immigration in pharmacoepidemiologic studiesHenrik Støvring
The Lancet Regional Health. Europe|January 6, 2025
How we count matters - infections are a major cause of death among patients with type 2 diabetesHenrik Støvring, Sarah Wild
Basic & Clinical Pharmacology & Toxicology|March 31, 2022
Incidence in pharmacoepidemiology-Basic definitions and types of misclassificationMikael Hoffmann, Henrik Støvring
Basic & Clinical Pharmacology & Toxicology|April 14, 2006
Templates for analysis of individual-level prescription dataJesper Hallas, Henrik Støvring
Basic & Clinical Pharmacology & Toxicology|November 22, 2022
Incidence in pharmacoepidemiology: A conceptual framework for incidence of a single substance or group of substances with statins as an exampleMikael Hoffmann, Henrik Støvring
Statistics in Medicine|September 29, 2005
Estimation of prevalence and incidence based on occurrence of health-related eventsHenrik Støvring, Werner Vach
The Lancet Regional Health. Europe|July 24, 2025
Cancer risk with GLP-1RA: what can real-world data really tell us?Niels Jessen, Henrik Støvring
BMC Research Notes|August 27, 2011
Simple parametric survival analysis with anonymized register data: A cohort study with truncated and interval censored event and censoring timesHenrik Støvring, Ivar S Kristiansen
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Ugeskrift for Laeger|January 14, 2004
[Occurrence of diabetes in Denmark: development of methods for registry-based assessment]Henrik Støvring
Ugeskrift for Laeger|December 10, 2002
[New biostatistical methods in general practice research. A literature review]Henrik Støvring
Pharmacoepidemiology and Drug Safety|April 26, 2007
Selection bias due to immigration in pharmacoepidemiologic studiesHenrik Støvring
The Lancet Regional Health. Europe|January 6, 2025
How we count matters - infections are a major cause of death among patients with type 2 diabetesHenrik Støvring, Sarah Wild
Basic & Clinical Pharmacology & Toxicology|March 31, 2022
Incidence in pharmacoepidemiology-Basic definitions and types of misclassificationMikael Hoffmann, Henrik Støvring
Basic & Clinical Pharmacology & Toxicology|April 14, 2006
Templates for analysis of individual-level prescription dataJesper Hallas, Henrik Støvring
Basic & Clinical Pharmacology & Toxicology|November 22, 2022
Incidence in pharmacoepidemiology: A conceptual framework for incidence of a single substance or group of substances with statins as an exampleMikael Hoffmann, Henrik Støvring
Statistics in Medicine|September 29, 2005
Estimation of prevalence and incidence based on occurrence of health-related eventsHenrik Støvring, Werner Vach
The Lancet Regional Health. Europe|July 24, 2025
Cancer risk with GLP-1RA: what can real-world data really tell us?Niels Jessen, Henrik Støvring
BMC Research Notes|August 27, 2011
Simple parametric survival analysis with anonymized register data: A cohort study with truncated and interval censored event and censoring timesHenrik Støvring, Ivar S Kristiansen
Pageof 14